Galanakis Nikolaos, Kehagias Elias, Matthaiou Nikolas, Samonakis Dimitrios, Tsetis Dimitrios
Interventional Radiology Unit, Department of Radiology, University Hospital of Heraklion, Faculty of Medicine, University of Crete, Heraklion, P.C. 71110, Greece.
Department of Gastroenterology, University Hospital of Heraklion, Faculty of Medicine, University of Crete, Heraklion, P.C. 71110, Greece.
Hepat Oncol. 2018 Sep 28;5(2):HEP07. doi: 10.2217/hep-2018-0001. eCollection 2018 Apr.
Hepatocellular carcinoma (HCC) is the sixth most common type of malignancy. Several therapies are available for HCC and are determined by stage of presentation, patient clinical status and liver function. Local-regional treatment options, including transcatheter arterial chemoembolization, radiofrequency ablation or microwave ablation, are safe and effective for HCC but are accompanied by limitations. The synergistic effects of combined transcatheter arterial chemoembolization and radiofrequency ablation/microwave ablation may overcome these limitations and improve the therapeutic outcome. The purpose of this article is to review the current literature on these combined therapies and examine their efficacy, safety and influence on the overall and recurrence-free survival in patients with HCC.
肝细胞癌（HCC）是第六大常见恶性肿瘤类型。HCC有多种治疗方法，具体取决于疾病分期、患者临床状况和肝功能。局部区域治疗方案，包括经动脉化疗栓塞、射频消融或微波消融，对HCC安全有效，但也存在局限性。经动脉化疗栓塞与射频消融/微波消融联合应用的协同效应可能克服这些局限性并改善治疗效果。本文旨在综述有关这些联合治疗的当前文献，并探讨其对HCC患者的疗效、安全性以及对总生存期和无复发生存期的影响。
